These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 12014598)

  • 21. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent.
    Ramasubbu R
    Arch Gen Psychiatry; 2002 May; 59(5):472; author reply 472-3. PubMed ID: 11982460
    [No Abstract]   [Full Text] [Related]  

  • 22. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.
    Takahashi H; Sugita T; Higuchi H; Shimizu T
    Hum Psychopharmacol; 2002 Mar; 17(2):95-8. PubMed ID: 12404698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
    Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O
    Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sertraline in the treatment of clozapine-induced obsessive-compulsive behavior.
    Rahman MS; Grace JJ; Pato MT; Priest B
    Am J Psychiatry; 1998 Nov; 155(11):1629-30. PubMed ID: 9812137
    [No Abstract]   [Full Text] [Related]  

  • 26. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluvoxamine in the treatment of corticosteroid-induced obsessive-compulsive disorder.
    Oulis P; Masdrakis VG; Florakis A; Papadimitriou GN
    Clin Neuropharmacol; 2009; 32(3):176-7. PubMed ID: 19483493
    [No Abstract]   [Full Text] [Related]  

  • 29. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
    Sun TF; Lin PY; Wu CK
    Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Case of obsessive-compulsive disorder associated with neuroleptics-induced deficit syndrome (NIDS): successfully treated by discontinuation of neuroleptics followed by SSRI].
    Machida N; Shiotsuka S; Semba J
    Seishin Shinkeigaku Zasshi; 2005; 107(7):667-73. PubMed ID: 16146185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Schizophrenia and obsessive-compulsive disorder.
    Devulapalli K; Nasrallah HA
    Am J Psychiatry; 2010 Nov; 167(11):1407-8. PubMed ID: 21041254
    [No Abstract]   [Full Text] [Related]  

  • 33. [The treatment of OCD].
    Sumitani S; Ohmori T
    Ryoikibetsu Shokogun Shirizu; 2003; (38):442-5. PubMed ID: 12877022
    [No Abstract]   [Full Text] [Related]  

  • 34. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Lafleur DL; Pittenger C; Kelmendi B; Gardner T; Wasylink S; Malison RT; Sanacora G; Krystal JH; Coric V
    Psychopharmacology (Berl); 2006 Jan; 184(2):254-6. PubMed ID: 16374600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder.
    Abdolhosseinzadeh S; Sina M; Ahmadiani A; Asadi S; Shams J
    J Clin Pharm Ther; 2019 Feb; 44(1):39-48. PubMed ID: 30315580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
    Berigan TR; Harazin JS
    J Clin Psychiatry; 1996 Dec; 57(12):594-5. PubMed ID: 9010126
    [No Abstract]   [Full Text] [Related]  

  • 38. Remission of treatment-resistant obsessive-compulsive disorder with 600 milligrams of fluvoxamine daily: a case report.
    Kocamer Şahin Ş; Demir B; Altindağ A
    Int Clin Psychopharmacol; 2023 Jul; 38(4):273-274. PubMed ID: 36752695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
    Ramasubbu R; Ravindran A; Lapierre Y
    Pharmacopsychiatry; 2000 Nov; 33(6):236-8. PubMed ID: 11147933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.
    Dell'Osso B; Allen A; Hollander E
    Expert Opin Pharmacother; 2005 Dec; 6(15):2727-40. PubMed ID: 16316311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.